Literature DB >> 17464993

Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.

Chih-Lin Lin1, Li-Ying Liao, Chun-Jen Liu, Ming-Whei Yu, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen, Jia-Horng Kao.   

Abstract

UNLABELLED: Chronic hepatitis B patients with high-normal serum ALT (levels of 0.5-1x upper limit of normal) are still at risk of liver disease progression. We thus investigated the correlation between serum ALT level and hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum ALT level (PNALT). Baseline clinical and virological features of 414 HBeAg-negative carriers, including 176 (42.5%) with low-normal ALT (levels of less than 0.5x upper limit of normal) and 238 (57.5%) with high-normal ALT, were compared. Compared with HBV carriers with low-normal ALT, those with high-normal ALT were older (41 vs. 37 years, P<0.001) and had a greater frequency of serum HBV DNA level>10(4) copies/ml (63.4% vs. 47.5%, P<0.001) as well as a higher prevalence of basal core promoter T1762/A1764 mutant (36.5% vs. 24.2%, P=0.01). Multivariate analysis showed that factors associated with a high-normal serum ALT level included male sex [odds ratio (OR), 1.82; 95% confidence interval (CI), 1.10-3.01, P=0.019], increasing age (OR, <30 years: 1, reference; 30-39 years: 2.43, 95% CI, 1.18-5.03, P=0.016; 40-49 years: 4.22, 95% CI, 1.99-8.93, P<0.001; >or=50 years: 4.06, 95% CI, 1.69-9.78, P=0.002) and serum HBV DNA level>10(4) copies/ml (OR, 1.83; 95% CI, 1.07-3.13, P=0.027).
CONCLUSION: HBeAg-negative patients with persistently normal ALT are not a homogenous group, and those with high-normal ALT share some of the characteristics that have been associated with adverse long-term outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464993     DOI: 10.1002/hep.21585

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

2.  Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT.

Authors:  Jin-Lin Cheng; Hong Zhao; Shi-Gui Yang; Er-Mei Chen; Wen-Qian Chen; Lan-Juan Li
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

3.  Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans.

Authors:  Yu-Nan Hsu; Calvin Q Pan; Ali Abbasi; Victor Xia; Raghav Bansal; Ke-Qin Hu
Journal:  Dig Dis Sci       Date:  2014-02-12       Impact factor: 3.199

4.  A severe case of esophageal ulcer causing a tight stricture despite long-term D-penicillamine treatment.

Authors:  Suna Yapali; Ilker Turan; Omer Ozutemiz; Oktay Tekesin
Journal:  Wien Klin Wochenschr       Date:  2014-09-19       Impact factor: 1.704

5.  Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation.

Authors:  Suna Yapali; Nizar Talaat; Robert J Fontana; Kelly Oberhelman; Anna S Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-17       Impact factor: 11.382

6.  Should chronic HBV infected patients with normal ALT treated: debate.

Authors:  Shiv Kumar Sarin; Manoj Kumar
Journal:  Hepatol Int       Date:  2008-03-04       Impact factor: 6.047

Review 7.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

8.  Chronic hepatitis B: the demise of the 'inactive carrier' phase.

Authors:  Apostolos Koffas; Manoj Kumar; Upkar S Gill; Ankur Jindal; Patrick T F Kennedy; S K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 10.  DNA-guided hepatitis B treatment, viral load is essential, but not sufficient.

Authors:  Rafael Bárcena Marugán; Silvia García Garzón
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.